Location: Home > Scientists
  Scientists
Name:
 Peng Yaojin
Subject:
 Biotechnology Law and bioethics, Intellectual Property and Standards, and Science and Innovation Policy
Tel/Fax:
  / 
E-mail:
 yaojin.peng@ioz.ac.cn
Address:
 Stem Cell and Regenerative Medicine Innovation Research Institute, No. 3, Datun Road, Chaoyang District, Beijing
More:
      
Resume:

Dr. Yaojin Peng is a dual-appointed Profess of Zhi-Yi  Chair at the Institute of Zoology, Chinese Academy of Sciences (CAS), and the Beijing Institute for Stem Cell and Regenerative Medicine. He serves as Director of the Center for Ethics of Science and Technology (CEST) and concurrently as Director of the Legal Affairs and Commercialization Platform.

Dr. Peng holds a Bachelor’s degree in Life Sciences, a Master’s degree in Law, and a Ph.D. in Law from Maastricht University, the Netherlands. His primary research interests include biotechnology law and bioethics, intellectual property and standards, and science and innovation policy. He has published over 40 papers as first author and/or corresponding author in leading international and domestic journals such as Nature Biotechnology, Nature Genetics, Cell Stem Cell. Dr. Peng led the drafting of China’s first group standard for ethical review in stem cell research, titled Technical Guidelines for Ethical Review of Human Stem Cell Research (T/CSCB 0009—2022). He has presided over several national and ministerial-level projects, including sub-projects under the National Key R&D Program of China, CAS Strategic Priority Research Programs, and the China Association for Science and Technology’s annual key research initiative on science and technology governance. In 2021, he was selected for the Youth Innovation Promotion Association of the Chinese Academy of Sciences, and received the Outstanding Individual Award for Public Engagement in Stem Cell Research from the Stem Cell Branch of the Chinese Society for Cell Biology.

Research Interests:

Biotechnology Law and bioethics, Intellectual Property and Standards, and Science and Innovation Policy

Teaching courses

Biomedical Law and Ethics (University of Chinese Academy of Sciences, Postgraduate Course)

Academic and Professional Affiliations

He concurrently serves as Director of the Ethics Committee for Life Sciences and Medicine of the Chinese Academy of Sciences (CAS), Member of the Expert Committee of the China Regenerative Medicine Innovation Platform, Deputy Secretary-General of the Academic Committee of the Center for Science, Technology and Governance at Tsinghua University, Secretary-General of the Ethics Working Committee of the Chinese Society for Cell Biology, Member of the International Organization for Standardization Technical Committee on Biotechnology (ISO/TC 276), and Member of the Public Policy Committee of the International Society for Stem Cell Research (ISSCR).

Previously, he was a doctoral researcher at the European Private Law Institute, a research fellow at the Institute for Globalisation and International Regulation at Maastricht University, and an academic advisor for the 17th Annual Conference of the European Policy for Intellectual Property (EPIP) Association. He also conducted legal research at the School of Law, Singapore Management University (SMU).

He is a peer reviewer for leading journals including Nature and Cell Stem Cell, and a scientific evaluator for major research funding agencies such as the Research Foundation – Flanders (FWO) and the European Science Foundation (ESF).

Awards and Honors:

Professional Activities:

Research Grants:

Selected Publications:
  1. Liang Yu, Ruohan Feng, Youhai Sun*, Yaojin Peng*, Governance of cross-border genomic data sharing through a human-rights approach (forthcoming)
  2. Ruohan Feng, Yaojin Peng*, Emerging Trends in Responsible Research: How China is Shaping Its Life and Health Data Governance Ecosystem  (forthcoming)
  3. Yaojin Peng*, Lulu Ding, Zhenyu Xiao, Moshi Song, Jianwei Lv, Guang-Hui Liu*, Ethical Concerns in Aging Research: Perspectives of Global Frontline Researchers, SCIENCE CHINA Life Sciences, Jun 19, 2024 (IF 9.1, SCI)
  4. Yaojin Peng*, Aijin Ma, Zhenyu Xiao, et al. Technical specifications for ethics review of human stem cell research. Cell Proliferation. 2023;e13556. (IF 8.755, SCI)
  5. Luxia Chen, Jianchao Gao, Ruohan Feng, Yaojin Peng*, The Variability of Judicial Decisions in the Stem Cell Industry in China, Cell Stem Cell, 2023, 30(10):1294-1298. (IF 25.269, SCI)
  6. Yaojin Peng*, Lulu Ding, Moshi Song, Zhenyu Xiao, Jianwei Lv, Guang-Hui Liu*, Acting on ethics and governance of aging research, Trends in Molecular Medicine, 2023, 29(6). (IF 15.272, SCI)
  7. Yaojin Peng*, Jianwei Lv, Lulu Ding, Xia Gong, Qi Zhou*, Responsible Governance of Human Germline Genome Editing in China, Biology of Reproduction, 2022 May 27;ioac114. . (IF 4.285, SCI)
  8. Lulu Ding, Zhenyu Xiao, Xia Gong, Yaojin Peng*, Knowledge Graphs of Ethical Concerns of Cerebral Organoids）, Cell Proliferation, 2022: e13239. (IF 8.755, SCI)
  9. Yaojin Peng*, Jianwei Lv, Zhenyu Xiao, Lulu Ding, Qi Zhou*, A framework for the responsible reform of the 14-day rule in human embryo research, Protein & Cell, 2022, 13(8):552–558. (IF 14.870, SCI)
  10. Zhenyu Xiao, Jianwei Lv, Siqi Zhao, Rosario Isasi, Xinwei Xie, Lei Dong, Yaojin Peng*, The Potential Effects of the United States Abortion Ruling on Global Embryo/Foetal and Stem Cell Research, Life Medicine. 2022 Nov 18.
  11. Jiani Cao, Jie Hao, Lei Wang, Yuanqing Tan, Yuchang Tian, Shiyu Li, Aijin Ma, Boqiang Fu, Jianwu Dai, Peijun Zhai, Peng Xiang, Yong Zhang, Tao Cheng*, Yaojin Peng*, Qi Zhou*, Tongbiao Zhao*. Developing standards to support the clinical translation of stem cells, STEM CELLS Transl Med. 2021; 10(S2): S85- S95. (IF: 7.655, SCI)
  12. Yaojin Peng*, Xiaoru Huang, Qi Zhou*, Ethical and Policy Considerations for Human Embryo and Stem Cell Research in China, Cell Stem Cell, 2020, 27(4). (IF 25.269, SCI)
  13. Jianwei Lv#, Yeyang Su#, Lingqiao Song, Xia Gong, Yaojin Peng*, Stem cell ‘therapy’ advertisements in China: infodemic, regulations and recommendations（, Cell Proliferation, 2020, 53(12). (IF 8.755, SCI)
  14. Yaojin Peng*, Patenting Human Embryonic Stem Cell Related Inventions in China: A Comparative Perspective, PhD thesis (Faculty of Law, Maastricht University, Netherlands, September 2018)
  15. Yaojin Peng*, The Patentability of Human Embryonic Stem Cell Technology in China, Nature Biotechnology, 2016, 34(1). DOI:10.1038/nbt.3417. (IF 43.113, SCI)
  16. Yaojin Peng*, The Morality and Ethics Governing CRISPR-Cas9 Patents in China, Nature Biotechnology, 2016, 34(6). DOI:10.1038/nbt.3590. (IF 43.113, SCI)
  17. Yaojin Peng*, Patent Term Extension in the Pharmaceutical Sector: An Asian Comparative Perspective, in The Future of Asian Trade Deals and IP (Kung-Chung Liu ed., Hart Publishing, forthcoming in 2019).
  18. Yaojin Peng, UW-Google Intermediary Liability Research Project: Privacy Protection in China, available at https://www.law.uw.edu/media/1404/china-intermediary-liability-of-isps-privacy.pdf.
  19. Nguyen Xuan-Thao, Trademark apologetic justice: China’s trademark jurisprudence on reputational harm. in Foreign scholars on Chinese law series: intellectual property law (translated into Chinese by Yaojin Peng*), in Intellectual Property Law of China, Encyclopedia of China Publishing House, 2018).
  20. Qianwen Chen, Siqi Zhao, Yaojin Peng, Organoids: technological innovation and ethical controversies（类器官：技术创新与伦理争议）, Synthetic Biology Journal《合成生物学》,2024, 5. DOI: 10.12211/2096-8280.2024-009.
  21. ShuaiShuai Niu , Lei1 Wang, TongBiao Zhao, Yaojin Peng*, Jie Hao*, Challenges and opportunities in the development of standardized stem cell resource centers（干细胞资源库的标准化建设：挑战和机遇）Sci Sin Vitae《中国科学：生命科学》, 2024, 54, doi: 10.1360/SSV-2024-0118. （CSCD，北大核心）
  22. Jianchao Gao, Yaojin Peng, Wei Wei, Shuang Lu, Chenyan Gao, Panorama of human embryo-derived cells in biomedicine and progress in their research and regulation（人胚胎来源细胞在生物医药领域的应用历史及研究和监管进展）Bulletin of Chinese Academy of Sciences《中国科学院院刊》, 2024,39(2):388-396. （CSCD，中文核心）
  23. Lulu Ding, Siqi Zhao, Yaojin Peng*, Tension between Technology and Ethics of Human-animal Chimera Research（人-动物嵌合体研究的技术-伦理张力）Studies in Science of Science 《科学学研究》, 2023.https://doi.org/10.16192/j.cnki.1003-2053.20230915.001. （CSSCI，北大核心）
  24. Luxia Chen, Xinwei Xie, Zhenyu Xiao, Yaojin Peng*, Challenges of mitochondrial replacement technology and its regulation（线粒体置换技术的挑战及其规制），Biomedical Transformation《生物医学转化》, 2022,3(04):96-105. （CSCD）
  25. Jianwei Lv，Yaojin Peng*，Reconstruction on the Withdrawal of Informed Consent System for Human Biological Samples（人体生物样本知情同意退出制度重塑），Science and Society《科学与社会》，2022,12(2):137-156.（CSSCI扩展板）
  26. Yaojin Peng*，Jianwei Lv，The challenges and solutions of the 14-day rule in human embryo research（人类胚胎研究“14天规则”的挑战与出路）, Journal of Dialectics of Nature《自然辩证法通讯》, 2022,44(10):77-86 (CSSCI，北大核心)（被评委《自然辩证法通讯》2022年度最受欢迎的10篇论文）
  27. Yaojin Peng, Qi Zhou*，China’s Strategies for Governance of Biotechnological Changes and New Ethical Challenges（应对生物技术变革与伦理新挑战的中国方略）, Bulletin of Chinese Academy of Sciences《中国科学院院刊》, 2021,36(11):1288-1297. （CSCD，中文核心）
  28. Yaojin Peng*, The Era of Synthetic Biology: Biosafety, Biosecurity and Governance（合成生物学时代：生物安全、生物安保与治理），Journal of International Security Studies《国际安全研究》，2020, 38(5): 29-57.（CSSCI）
  29. Yaojin Peng*, Li Wei, Ethical issues and the governance of life science and technology: A case study on human-animal chimeras（生命科技伦理问题与治理策略——以人-动物嵌合体研究为例）, Science & Technology Review（科技导报），2020, 38(5): 42-49.（CSCD，中文核心）
  30. Qi Zhou*, Yaojin Peng, The Era of Biotechnology and Biosafety（这是生物技术的时代，也是生物安全的时代）, Journal of Engineering Studies（工程研究——跨学科视野中的工程），2020, 12(1).（CSCD，中文核心）
  31. Yaojin Peng*，Designer baby: How to face it（“设计婴儿”：我们将怎样面对）, Frontier Science（前沿科学）, 2019(3): 93-96.
  32. Yaojin Peng*, Intellectual Property Protection Concerning Stem Cell Research in China: Predicament and Solutions（中国干细胞知识产权保护的困境与对策）, Chinese Bulletin of Life Science（生命科学）, 2016, 28(8).（CSCD、北大核心）
  33. Yaojin Peng*, Employees’ Invention Compensation Regime in the Netherlands and Its Enlightenment to China（荷兰职务发明奖酬制度及其借鉴意义）, Journal of Fujian Jiangxia University（福建夏学院学报）, 2017, 7(4): 29-38.
  34. Yong Wan, Jie Wang, Tianxiang He, Yaojin Peng, Zijiao Cheng, The Protection of Privacy in China（中国的隐私保护）, Journal of Shantou University （汕头大学学报）, 2017, 33(11) .

Participation standards

  1. Yu M, Lei W, Cao J, Wang L, Ma A, Zhao ZA, Yang HT, Shen Z, Lan F, Cao F, Liang P, Pei X, Xiang AP, Yu J, Zhang Y, Zhang Y, Li Q, Zhou J, Wei J, Peng Y, Zhu H, Liang L, Cao N, Fu B, Hao J, Zhao T, Hu S. Requirements for human cardiomyocytes（人类心肌细胞的规范要求）. Cell Prolif. 2022 Apr;55(4):e13150. doi: 10.1111/cpr.13150.
  2. Chen X, Huang J, Wu J, Hao J, Fu B, Wang Y, Zhou B, Na T, Wei J, Zhang Y, Li Q, Hu S, Zhou J, Yu J, Wu Z, Zhu H, Cao J, Wang L, Peng Y, Liang L, Ma A, Zhang Y, Zhao T, Xiang AP. Human mesenchymal stem cells. Cell Prolif. 2022 Apr;55(4):e13141. doi: 10.1111/cpr.13141.
  3. Peng Z, Wu J, Hu S, Ma A, Wang L, Cao N, Zhang Y, Li Q, Yu J, Meng S, Na T, Shi X, Li M, Liu H, Qian L, Tian E, Lin F, Cao J, Peng Y, Zhu H, Liang L, Hao J, Zhao T, Cheng X, Pan G. Requirments for primary human hepatocyte. Cell Prolif. 2022 Apr;55(4):e13147. doi: 10.1111/cpr.13147.
  4. Wang L, Cao J, Peng Y, Fu B, Jin Z, Hu Y, Wu W, Xiang AP, Hu S, Yu J, Zhang Y, Wei J, Zhang Y, Li Q, Zhou J, Zhai P, Zhu H, Liang L, Ma A, Stacey G, Zhao T, Hao J. Human retinal pigment epithelial cells. Cell Prolif. 2022 Apr;55(4):e13153. doi: 10.1111/cpr.13153.
  5. Nan X, Zhang B, Hao J, Yue W, Fu B, Qu M, Zhang Y, Wang H, Fang F, Wei J, Li Q, Hu S, Yu J, Gao Y, Liu Q, Cao J, Wang L, Peng Y, Zhu H, Liang L, Ma A, Zhou J, Zhao T, Pei X. Requirements for human haematopoietic stem/progenitor cells. Cell Prolif. 2022 Apr;55(4):e13152. doi: 10.1111/cpr.13152.
  6. Zhang Y, Wei J, Cao J, Zhang K, Peng Y, Deng H, Kang J, Pan G, Zhang Y, Fu B, Hu S, Na J, Liu Y, Wang L, Liang L, Zhu H, Zhang Y, Jin ZB, Hao J, Ma A, Zhao T, Yu J. Requirements for human-induced pluripotent stem cells. Cell Prolif. 2022 Apr;55(4):e13182. doi: 10.1111/cpr.13182.